|
1
|
Wei WI and Sham JS: Nasopharyngeal
carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu Z, Luo W, Zhou Y, et al: Potential
tumor suppressor NESG1 as an unfavorable prognosis factor in
nasopharyngeal carcinoma. PLoS One. 6:e278872011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alajez NM, Shi W, Hui AB, Bruce J,
Lenarduzzi M, Ito E, Yue S, O’Sullivan B and Liu FF: Enhancer of
zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal
carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell
Death Dis. 1:e852010. View Article : Google Scholar
|
|
4
|
Wang S and Fang W: Increased expression of
hepatoma-derived growth factor correlates with poor prognosis in
human nasopharyngeal carcinoma. Histopathology. 58:217–224. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fang W, Li X, Jiang Q, et al:
Transcriptional patterns, biomarkers and pathways characterizing
nasopharyngeal carcinoma of Southern China. J Transl Med. 6:322008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chua DT, Ma J, Sham JS, Mai HQ, Choy DT,
Hong MH, Lu TX and Min HQ: Long-term survival after cisplatin-based
induction chemotherapy and radiotherapy for nasopharyngeal
carcinoma: a pooled data analysis of two phase III trials. J Clin
Oncol. 23:1118–1124. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Razak AR, Siu LL, Liu FF, Ito E,
O’Sullivan B and Chan K: Nasopharyngeal carcinoma: the next
challenges. Eur J Cancer. 46:1967–1978. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Costa RH, Kalinichenko VV, Holterman AX
and Wang X: Transcription factors in liver development,
differentiation, and regeneration. Hepatology. 38:1331–1347. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ye H, Kelly TF, Samadani U, Lim L, Rubio
S, Overdier DG, Roebuck KA and Costa RH: Hepatocyte nuclear factor
3/fork head homolog 11 is expressed in proliferating epithelial and
mesenchymal cells of embryonic and adult tissues. Mol Cell Biol.
17:1626–1641. 1997.PubMed/NCBI
|
|
10
|
Wang IC, Chen YJ, Hughes D, Petrovic V,
Major ML, Park HJ, Tan Y, Ackerson T and Costa RH: Forkhead box M1
regulates the transcriptional network of genes essential for
mitotic progression and genes encoding the SCF (Skp2-Cks1)
ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kalin TV, Wang IC, Ackerson TJ, Major ML,
Detrisac CJ, Kalinichenko VV, Lyubimov A and Costa RH: Increased
levels of the FoxM1 transcription factor accelerate development and
progression of prostate carcinomas in both TRAMP and LADY
transgenic mice. Cancer Res. 66:1712–1720. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim IM, Ackerson T, Ramakrishna S, et al:
The forkhead box M1 transcription factor stimulates the
proliferation of tumor cells during development of lung cancer.
Cancer Res. 66:2153–2161. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu M, Dai B, Kang SH, et al: FoxM1B is
overexpressed in human glioblastomas and critically regulates the
tumorigenicity of glioma cells. Cancer Res. 66:3593–3602. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW,
Cheung AN and Ngan HY: Over-expression of FOXM1 transcription
factor is associated with cervical cancer progression and
pathogenesis. J Pathol. 215:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D,
Huang S, Tan D and Xie K: Critical role and regulation of
transcription factor FoxM1 in human gastric cancer angiogenesis and
progression. Cancer Res. 69:3501–3509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tiwari N, Gheldof A, Tatari M and
Christofori G: EMT as the ultimate survival mechanism of cancer
cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Banerjee S, Kong D, Li Y and
Sarkar FH: Down-regulation of forkhead box M1 transcription factor
leads to the inhibition of invasion and angiogenesis of pancreatic
cancer cells. Cancer Res. 67:8293–8300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lynch TP, Ferrer CM, Jackson SR, Shahriari
KS, Vosseller K and Reginato MJ: Critical role of O-Linked
β-N-acetylglucosamine transferase in prostate cancer invasion,
angiogenesis, and metastasis. J Biol Chem. 287:11070–11081. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xue YJ, Xiao RH, Long DZ, et al:
Overexpression of FoxM1 is associated with tumor progression in
patients with clear cell renal cell carcinoma. J Transl Med.
10:2002012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Ahmad A, Li Y, Banerjee S, Kong D
and Sarkar FH: Forkhead box M1 transcription factor: A novel target
for cancer therapy. Cancer Treat Rev. 36:151–156. 2010. View Article : Google Scholar :
|
|
21
|
Chen H, Yang C, Yu L, Xie L, Hu J, Zeng L
and Tan Y: Adenovirus-mediated RNA interference targeting FOXM1
transcription factor suppresses cell proliferation and tumor growth
of nasopharyngeal carcinoma. J Gene Med. 14:231–240. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang C, Chen H, Yu L, Shan L, Xie L, Hu J,
Chen T and Tan Y: Inhibition of FOXM1 transcription factor
suppresses cell proliferation and tumor growth of breast cancer.
Cancer Gene Ther. 20:117–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kwok JM, Myatt SS, Marson CM, Coombes RC,
Constantinidou D and Lam EW: Thiostrepton selectively targets
breast cancer cells through inhibition of forkhead box M1
expression. Mol Cancer Ther. 7:2022–2032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hussain AR, Al-Jomah NA, Siraj AK,
Manogaran P, Al-Hussein K, Abubaker J, Platanias LC, Al-Kuraya KS
and Uddin S: Sanguinarine-dependent induction of apoptosis in
primary effusion lymphoma cells. Cancer Res. 67:3888–3897. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uddin S, Bavi P, Siraj AK, et al: Leptin-R
and its association with PI3K/AKT signaling pathway in papillary
thyroid carcinoma. Endocr Relat Cancer. 17:191–202. 2010.
View Article : Google Scholar
|
|
26
|
Bhat UG, Halasi M and Gartel AL: FoxM1 is
a general target for proteasome inhibitors. PLoS One. 4:e65932009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pilarsky C, Wenzig M, Specht T, Saeger HD
and Grützmann R: Identification and validation of commonly
overexpressed genes in solid tumors by comparison of microarray
data. Neoplasia. 6:744–750. 2004. View Article : Google Scholar
|
|
28
|
Bektas N, Haaf A, Veeck J, Wild PJ,
Lüscher-Firzlaff J, Hartmann A, Knüchel R and Dahl E: Tight
correlation between expression of the forkhead transcription factor
FOXM1 and HER2 in human breast cancer. BMC Cancer. 8:422008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
30
|
Chandran UR, Ma C, Dhir R, Bisceglia M,
Lyons-Weiler M, Liang W, Michalopoulos G, Becich M and Monzon FA:
Gene expression profiles of prostate cancer reveal involvement of
multiple molecular pathways in the metastatic process. BMC Cancer.
7:642007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dai B, Kang SH, Gong W, Liu M, Aldape KD,
Sawaya R and Huang S: Aberrant FoxM1B expression increases matrix
metal-loproteinase-2 transcription and enhances the invasion of
glioma cells. Oncogene. 26:6212–6219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kraljevic Pavelic S, Sedic M, Bosnjak H,
Spaventi S and Pavelic K: Metastasis: new perspectives on an old
problem. Mol Cancer. 10:222011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gavert N and Ben-Ze’ev A:
Epithelial-mesenchymal transition and the invasive potential of
tumors. Trends Mol Med. 14:199–209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: new insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Grünert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Araki K, Shimura T, Suzuki H, Tsutsumi S,
Wada W, Yajima T, Kobayahi T, Kubo N and Kuwano H: E/N-cadherin
switch mediates cancer progression via TGF-β-induced
epithelial-to-mesenchymal transition in extrahepatic
cholangio-carcinoma. Br J Cancer. 105:1885–1893. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nakajima S, Doi R, Toyoda E, et al:
N-cadherin expression and epithelial-mesenchymal transition in
pancreatic carcinoma. Clin Cancer Res. 10:4125–4133. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mandal M, Myers JN, Lippman SM, et al:
Epithelial to mesen-chymal transition in head and neck squamous
carcinoma: association of Src activation with E-cadherin
down-regulation, vimentin expression, and aggressive tumor
features. Cancer. 112:2088–2100. 2008. View Article : Google Scholar : PubMed/NCBI
|
